Systematic review and network meta-analysis of treatment strategies for asymptomatic carotid disease. by Barkat, M et al.
1SCIENTIfIC RepoRTS |  (2018) 8:4458  | DOI:10.1038/s41598-018-22356-z
www.nature.com/scientificreports
Systematic review and network 
meta-analysis of treatment 
strategies for asymptomatic carotid 
disease
Mohamed Barkat1,2, Iain Roy  1,2, Stavros A. Antoniou  3, Francesco Torella1,4 &  
George A. Antoniou5
We aim to perform a systematic review and meta-analysis to investigate outcomes of treatment 
strategies for asymptomatic carotid disease. We searched electronic bibliographic sources (MEDLINE, 
EMBASE, CINAHL and CENTRAL) to identify randomised controlled trials (RCT) reporting comparative 
outcomes of carotid endarterectomy (CEA), carotid stenting (CAS) and best medical therapy (BMT) in 
asymptomatic carotid disease. We performed pairwise meta-analysis applying random or fixed-effects 
models and reported the results as the odds ratio (OR) or risk difference (RD) and 95% confidence 
interval (CI). We also performed a network meta-analysis and obtained a hierarchy of the competing 
interventions using rankograms and the surface under the cumulative ranking curve and mean ranks. 
Stroke and death within 30 days and during follow up were the primary outcome endpoints. Eleven 
RCTs were identified reporting a total of 8,954 patients. Compared to BMT, CEA reduces the odds of 
long-term mortality (OR 0.70, 95% CI 0.43, 1.12) and ipsilateral stroke (OR 0.59 95% CI 0.50, 0.71). 
Network meta-analyses league table demonstrated that BMT is superior to CEA and CAS in terms of 
perioperative stroke risk and mortality. CEA is the preferred method to reduce the long-term risk of 
ipsilateral stroke and mortality for patients with asymptomatic carotid disease.
Stroke is the second leading cause of disability in Europe after ischaemic heart disease and the sixth leading cause 
worldwide1. In Europe, the annual cost of stroke is an estimated €27 billion: €18.5 billion for direct costs and 
€8.5 billion for indirect costs2.
Carotid atherosclerosis is a significant cause of ischemic stroke and transient ischemic attack (TIA)3,4. The 
optimal treatment for patients with asymptomatic carotid disease remains controversial with no clear consensus 
to recommend the best therapy for them. Carotid endarterectomy (CEA) has been suggested to be superior in 
preventing stroke compared to medical therapy alone in asymptomatic patients with >70% stenosis5. Carotid 
stenting (CAS) has emerged as a therapeutic alternative to endarterectomy for the treatment of severe carotid 
stenosis. The results of randomized trials comparing stenting and endarterectomy have been conflicting6,7.
In 2011, the American Heart Association (AHA) published its updated guidelines on the role of CEA and 
CAS in asymptomatic patients8. Its recommendations were based on two landmarks randomised clinical trials 
published in 1995 and 20049,10. However, medical therapy in these trials was not comparable with current stand-
ards. Medical therapy for stroke prevention has improved since these original trials, with more widespread use 
of statins, more active lowering of blood pressure and more effective antiplatelet regimes. More recent data from 
the Oxford Vascular Study (OXVASC) demonstrate a stroke risk of only 0.3% per year attributable to ipsilateral 
asymptomatic carotid stenosis treated with best medical therapy (BMT) alone11.
In view of the improving medical therapy for stroke prevention with more widespread use of statins, more 
active lowering of blood pressure and more effective antiplatelet regimes, there is currently uncertainty as to 
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whether carotid intervention (endarterectomy or stenting) provides clinical benefits and superior outcomes 
over optimised medical therapy in patient cohorts with asymptomatic carotid disease. Our systematic review 
investigated outcomes of treatment strategies for asymptomatic carotid disease applying network meta-analytic 
techniques.
Results
Literature search results. The initial literature search identified a total of 523 records. Two additional rele-
vant records were identified through manual search of the references lists. Out of the 525 articles 23 articles were 
relevant to this study and the full-texts were assessed for eligibility criteria. Eleven articles9,10,12–20 met the inclu-
sion criteria and were incorporated in the meta-analysis. Figure 1 summarizes the results of the literature search.
Description of included studies. The characteristics of the selected studies and the specific study popula-
tion baseline demographics and clinical characteristics are summarised in Tables 1 and 2, respectively.
CEA vs. CAS vs. BMT. SPACE-212 is the only RCT that was planned as a three-armed trial, namely BMT alone 
vs. CEA plus BMT vs. CAS plus BMT. This trial was powered to randomize more than 3000 patients over a 5-year 
period. Because of slow patient recruitment, the three-arm study design was amended in July 2013 to become 
two parallel randomized studies (BMT alone vs. CEA plus BMT and BMT alone vs. CAS plus BMT). However, 
again due to slow recruitment, the trial was ceased after enrolment of 513 patients over a 5-year period (CEA plus 
BMT, n = 203; CAS plus BMT, n = 197; and BMT alone, n = 113). Patients were followed up for up to five years to 
produce long-term primary efficacy data.
CEA vs. BMT. We identified five RCTs9,10,15,19,20 reporting comparative outcomes of CEA vs. BMT for asymp-
tomatic carotid disease, which were published between 1992 and 2015. The overall study population comprised 
of 5349 patients, 2663 in the CEA group and 2686 in the BMT group. Single antiplatelet therapy in the form of 
aspirin was used in both treatment groups in all but one trial20, in which CEA patients received no antiplatelet 
therapy. BMT as per current guidelines were used in only one trial15, the remaining trail did not provide elements 
of their BMT protocol. In ACST 110 the use of lipid lowering drugs improved significantly during the study period 
(initially only 7% and at the end of the trail 82%). Follow up ranged between two and ten years. There were no 
significant differences in baseline demographics and clinical characteristics between the CEA and BMT groups.
CEA vs. CAS. We identified five RCTs13,14,16–18 reporting comparative outcomes of CEA vs. CAS for asympto-
matic carotid disease, which were published between 2008 and 2016. The studies included a total of 3092 patients; 
1181 of them underwent CEA and the remaining 1911 underwent CAS. Patients in the CEA group received single 
antiplatelet therapy with aspirin, whereas those undergoing CAS received dual antiplatelet therapy (aspirin and 
Figure 1. Study flow diagram. BMT, best medical therapy; CAS, carotid stenting; CEA, carotid endarterectomy; 
RCT, randomised controlled trial.
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clopidogrel). Follow up ranged from three to ten years. There were no significant differences in baseline demo-
graphics and clinical characteristics between the CEA and BMT groups.
Risk of bias assessment. Random sequence generation and allocation concealment methods were ade-
quately described in all but one trial14, which did not state patient selection methods. Due to the nature of inter-
vention, blinding of participants and personnel was not possible resulting in a high risk of performance bias. In 
six RCTs9,10,12,18–20, blinding of outcome assessors was adequately described, whereas in the remaining trials, this 
parameter was inadequately reported. Five RCTs12,13,15,18,20 were found to have incomplete outcome data (attrition 
bias). Four RCTs12,13,15,18 were terminated early, three due to slow enrolment and one due to an unacceptable com-
plication rate in the CEA group20. No reporting bias was identified in any of the trials. The risk of bias assessment 











2009–2014 513 CEA: 203 CAS: 197 BMT: 113
CEA: Aspirin CAS: 
Aspirin + clopidogrel
BMT: Aspirin
Patients aged 50–85 years with 
a 70–99% ICA stenosis based 
on ultrasound without stroke/
TIA symptoms within the 
preceding 180 days
Primary safety endpoint: combined rate 
of death/any stroke within 30 days after 
CEA or CAS.
The primary efficacy endpoint: 
cumulative rate of death/any stroke 
within 30 days plus the rate of ipsilateral 








2005–2013 1453 CEA: 364 CAS:1089
CEA: Aspirin CAS: 
Aspirin + clopidogrel
Patients aged 79 years or 
younger with 70–99% ICA 
stenosis without symptoms 
during the previous 180 days. 
In the absence of substantial
(>60%) contralateral carotid 
stenosis
Primary end point: 30-day incidence of 
stroke (Major or minor), death or MI. Or 





No records 136 CEA: 68 CAS:68 CEA: Aspirin CAS: Aspirin + clopidogrel
Asymptomatic (for 6 months) 
patient with severe carotid 
atherosclerosis with >70% 
ICA stenosis
Primary end point was the 30-day 





2009–2014 55 CEA: 31 BMT: 24 CEA: Aspirin BMT: Aspirin
Asymptomatic patient aged 
<80, with severe carotid 
atherosclerosis with 70–79% 
ICA stenosis, no stroke/TIA in 
last 6 months
Nonfatal ipsilateral stroke and death 





108 centres US 9 
centres Canada
2000–2008 1181 CEA: 587 CAS: 594
CEA: Aspirin CAS: 
Aspirin + clopidogrel 
or ticlopidine
ICA stenosis of ≥60% on 
angiography, ≥70% on 
ultrasound, or ≥80% on 
CTA/MRA if the stenosis on 
ultrasonography was 50 to 69%
The primary end point: any stroke, 
myocardial infarction, or death during 
the periprocedural period or ipsilateral 






126 centres 30 
countries
1993–2003 3120 CEA:1560 BMT:1560
All patients Aspirin 
or Clopidogrel
Asymptomatic patient (last 6 
months) with carotid stenosis 
of ≥60%
The primary endpoint: perioperative 
mortality and morbidity (death or stroke 






1998–2002 85 CEA: 42 CAS: 43
All patients on 
Aspirin and 
Clopidogrel
Asymptomatic patient with 
carotid stenosis of more than 
80%
The primary endpoint: perioperative 








2000–2002 237 CEA: 120 CAS: 117
CEA: Aspirin CAS: 
Aspirin + clopidogrel
Asymptomatic patients with 
at least 80% ICA stenosis on 
duplex ultrasonography and at 
least one coexisting condition 
that potentially increased 
the risk posed by carotid 
endarterectomy
The primary end point: the cumulative 
incidence of death, stroke, or MI within 
30 days after the procedure or death or 









1987–1993 1659 CEA: 825 BMT: 834
CEA: Aspirin BMT: 
Aspirin
Patients aged 40–79 with 
asymptomatic ICA stenosis 
of ≥60%
The primary endpoints: TIA, all death/
stroke within 30 days after CEA or 42 
days in BMT group (to reflect 12 day 
delay to surgery).







1983–1987 444 CEA: 211 BMT: 233
CEA: Aspirin BMT: 
Aspirin
Patients with asymptomatic 
ICA stenosis of ≥50%)
The primary end point: cumulative 
incidence of TIA, death, stroke within 
30 days after the procedure or death or 







months 71 CEA: 36 BMT: 35
CEA: None
BMT: Aspirin
Patients with asymptomatic 
carotid stenosis (≥50% linear 
stenosis or 75% cross sectional 
area stenosis)
The primary end point of the trial was 
the cumulative incidence of TIA, any 
stroke and death.
1.9 years
Table 1. Study characteristics. BMT, best medical therapy; CAS, carotid stenting; CEA, carotid endarterectomy; 
CTA, computed tomographic angiography; ICA, internal carotid artery; MI, myocardial infarction; MRA, 
magnetic resonance angiography; RCT, randomised controlled trial; TIA, transient ischemic attack.
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Effects of interventions. Pair-wise meta-analysis. Forest plots of comparisons of CEA vs. BMT and CEA 
versus CAS are presented in Figs 3 and 4, respectively.
CEA vs. BMT. Thirty-day ipsilateral stroke. Data on 30-day ipsilateral stroke were reported in all five stud-
ies9,10,15,19,20. In the CEA group (2835 patients), the incidence of 30-day ipsilateral stroke was 1.6%, whereas in the 
BMT group (2775 patients), the incidence was 0.4% (RD: 0.01, 95% CI: 0.01–0.02, P < 0.00001). We found no 
evidence of heterogeneity among the studies (I2 = 0%, P = 0.44). Excluding trials that were judged to be at high 
risk of bias in two or more domains (ACAS9, ACST-110, SPACE-212) showed no difference between the treatment 
groups (RD: 0.02, 95% CI: −0.00–0.04, P = 0.11). The recruitment period started after 2000 in one trial only 
(SPACE-2 trial12), which found no significant difference in 30-day stroke risk between treatments (OR: 5.12, 95% 
CI: 0.27–95.97, P = 0.27). The GRADE level of evidence for this outcome was judged to be high.
Thirty-day mortality. Data on 30-day mortality were reported in all five studies9,10,15,19,20. The 30-day mortality 
rate was 0.8% in the CEA group (2853 patients) and 0.1% in the BMT group (2775 patients) (RD: 0.01, 95% CI: 
0.00–0.01, P = 0.0006). The likelihood of between-study heterogeneity was low (I2 = 18%, P = 0.3). Excluding 
trials that were judged to be at high risk of bias in two or more domains (ACAS9, ACST-110, SPACE-212) showed 
no difference between the treatment groups (RD: 0.01, 95% CI: −0.01–0.03, P = 0.19). The recruitment period 
started after 2000 in one trial only (SPACE-2 trial12), which reported no mortality within 30 days in either group. 
The GRADE level of evidence for this outcome was judged to be high.
Thirty-day ipsilateral minor stroke/TIA. Data on 30-day minor stroke/TIA were reported in three trials10,19,20. 
In the CEA group (1807 patients), the incidence of minor stroke/TIA at 30-days was 1.2%, while in the BMT 
group (1828 patients), the incidence was 0.7% (OR: 1.63, 95% CI: 0.81–3.27, P = 0.17). There was no evidence of 
significant statistical heterogeneity among the studies (I2 = 46%, P = 0.16). Excluding the trial that was judged to 
be at high risk of bias in two or more domains (ACST-110) showed no difference between the treatment groups 
(OR: 0.61, 95% CI: 0.14–2.55, P = 0.5). The recruitment period started before 2000 in all trials included in the 
analysis. The GRADE level of evidence for this outcome was judged to be high.
Thirty-day MI. Data on 30-day MI were reported in three studies10,19,20. In the CEA group (1807 patients), MI 
within 30 days of treatment occurred in 1.2% of patients, whereas in the BMT group (1828 patients), MI within 
30 days occurred in 0.1% (OR: 12.07, 95% CI: 2.82–51.6, P = 0.0008). There was no evidence of statistical hetero-
geneity among the studies (I2 = 0%, P = 0.92). Excluding the trial that was judged to be at high risk of bias in two 
or more domains (ACST-110) showed a difference in favour of BMT (OR: 8.78, 95% CI: 1.08–71.21, P = 0.04). The 
recruitment period started before 2000 in all trials included in the analysis. The GRADE level of evidence for this 
outcome was judged to be high.
Ipsilateral stroke during follow up. Data on ipsilateral stroke during follow up were reported in four stud-
ies9,10,15,19. In the CEA group (2627 patients), the incidence of stroke was 8.4%, whereas in the BMT group (2651 
patients), ipsilateral stroke occurred in 13.4% of patients (OR: 0.59, 95% CI: 0.49–0.7, P < 0.00001). We found 
no evidence of statistical heterogeneity among the selected studies (I2 = 0%, P = 0.49). Excluding trials that were 
judged to be at high risk of bias in two or more domains (ACAS9, ACST-110, AMTEC15) showed no difference 
between the treatment groups (OR: 0.48, 95% CI: 0.22–1.03, P = 0.06). Only one trial (ACST-110) provided 
follow-up data >5 years; it found a significance difference in stroke risk in favour of CEA (OR: 0.59, 95% CI: 
0.48–0.73, P < 0.00001). The recruitment period started after 2000 in one trial only (AMTEC15), which found no 
significant difference in the follow-up stroke risk between treatments (OR: 0.13, 95% CI: 0.01–1.17, P = 0.07). The 
GRADE level of evidence for this outcome was judged to be high.
Mortality during follow up. Data on long-term mortality were reported in three studies9,10,15. The mortality rate 
during follow up was 5.1% in the CEA group (2416 patients) and 6.6% in the BMT group (2418 patients) (OR: 
0.75, 95% CI: 0.59–0.96, P = 0.02). We found no evidence of significant statistical heterogeneity among the studies 
(I2 = 64%, P = 0.06). All three trials included in this analysis were at high risk of bias in two or more domains. 
Only one trial (ACST-110) provided follow-up data >5 years; it found a significance difference in mortality in 
favour of CEA (OR: 0.56, 95% CI: 0.38–0.84, P = 0.005). The recruitment period started after 2000 in one trial 
only (AMTEC15), which found no significant difference in mortality risk during follow up between treatments 
(OR: 0.17, 95% CI: 0.02–1.6, P = 0.12). The GRADE level of evidence for this outcome was judged to be high.
Ipsilateral minor stroke/TIA during follow up. Data on long-term ipsilateral minor stroke/TIA were reported in 
two trials19,20. During follow up, ipsilateral minor stroke/TIA occurred in 3.2% in the CEA group (247 patients) 
and in 1.9% in the BMT group (268 patients) (OR: 0.27, 95% CI, 0.12–0.59, P = 0.001). We identified no evidence 
of statistical heterogeneity (I2 = 0%, P = 0.86). Both trials were found to be of risk of bias in less than two domains. 
Neither reported follow up >5 years. The recruitment period started before 2000 in both trials included in the 
analysis. The GRADE level of evidence for this outcome was judged to be high.
MI during follow up. Data on MI during follow up were reported in two studies15,20. MI during the follow-up 
period occurred in one patient (1.5%) in the CEA group (67 patients) and in two patients (3.3%) in the BMT 
group (59 patients) (OR: 0.57, 95% CI: 0.1–3.38, P = 0.54). There was no evidence of statistical heterogeneity 
between the two studies (I2 = 44%, P = 0.18). One trial (AMTEC15) was judged to be of high risk of bias in more 
than two domains; excluding this trial revealed no difference in the risk of MI during follow up between treat-
ment groups (OR: 3, 95% CI: 0.12–76.16, P = 0.51). None of the trials reported follow up >5 years. The recruit-
ment period started after 2000 in one trial only (AMTEC15), which found no significant difference in mortality 
risk during follow up (OR: 0.14, 95% CI: 0.01–3.12, P = 0.22). The GRADE level of evidence for this outcome was 
judged to be high.
CEA vs. CAS. Thirty-day ipsilateral stroke. Data on ipsilateral stroke within 30 days of treatment were reported 
in all five studies13,14,16–18. The 30-day incidence of ipsilateral stroke was 1% in the CEA group (1264 patients) and 
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No records No records n/a n/a
Table 2. Patient demographic and clinical characteristics. BMT, best medical therapy; CAD, coronary artery 
disease; CAS, carotid stenting; CEA, carotid endarterectomy; COPD, chronic obstructive pulmonary disease; 
CPD, cerebral protection device; CRF, chronic renal failure; CTA, computed tomographic angiography; DM, 
diabetes mellitus; DSA, digital subtraction angiography; GA, general anaesthetic; HTN, hypertension; ICA, 
internal carotid artery; MI, myocardial infarction; MRA, magnetic resonance angiography; RA, regional 
anaesthetic; RCT, randomised controlled trial; SD, standard deviation; TCD, transcranial doppler; TIA, 
transient ischemic attack.
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1.2% in the CAS group (1991 patients) (RD: −0.01, 95% CI: −0.01–0.00, P = 0.16). There was no evidence of sta-
tistical heterogeneity among the studies (I2 = 0%, P = 0.56). All trials were judged to be at high risk of bias in two 
or more domains. The recruitment period started before 2000 in one trial (Kentucky);17 excluding this trial from 
the analysis showed no difference in the stroke risk within 30 days between CEA and CAS (RD: −0.01, 95% CI: 
−0.01–0.00, P = 0.15). The GRADE level of evidence for this outcome was judged to be moderate.
Thirty-day mortality. Data on 30-day mortality were reported in all five trials13,14,16–18. Mortality was 0.7% 
in the CEA group (1264 patients) and 0.8% in the CAS group (1991 patients) (RD: −0.00, 95% CI: −0.01–0.00, 
P = 0.27). We found no evidence of statistical heterogeneity (I2 = 31%, P = 0.21). All trials were judged to be at 
high risk of bias in two or more domains. Excluding the trial where the recruitment period started before 2000 
(Kentucky)17 revealed no difference in the 30-day mortality risk between CEA and CAS (RD: −0.00, 95% CI: 
−0.01–0.00, P = 0.26). The GRADE level of evidence for this outcome was judged to be moderate.
Thirty-day ipsilateral minor stroke/TIA. Data on ipsilateral minor stroke/TIA occurring within 30 days of treat-
ment were reported in three trials13,14,17. In the CEA group (474 patients), the 30-day incidence of minor stroke/
TIA was 1.1%, while in the CAS group (1200 patients), it was 1.9% (RD: −0.01, 95% CI: −0.02–0.01, P = 0.23). 
We found no significant between-study heterogeneity (I2 = 0%, P = 0.86). All three trials were judged to be at 
high risk of bias in two or more domains. Excluding the trial with recruitment starting before 2000 (Kentucky)17 
revealed no difference in the risk of minor stroke/TIA (RD: −0.01, 95% CI: −0.02–0.00, P = 0.21). The GRADE 
level of evidence for this outcome was judged to be moderate.
Thirty-day MI. Data on MI within 30 days of treatment were reported in three studies13,14,16. In the CEA 
group (1019 patients), MI occurred in 1.6% of patients, whereas in the CAS group (1751 patients), MI within 30 
days of treatment occurred in 0.7% (RD: 0.01, 95% CI: −0.00–0.02, P = 0.13). The statistical heterogeneity was 
insignificant (I2 = 0%, P = 0.67). All trials were judged to be at high risk of bias in two or more domains, and their 
recruitment period started after 2000. The GRADE level of evidence for this outcome was judged to be moderate.
Ipsilateral stroke during follow up. Data on long-term ipsilateral stroke were reported in two studies13,18. The 
stroke rate was 4.3% in the CEA group (484 patients) and 3% in the CAS group (1206 patients) (OR: 1.05, 95% 
CI: 0.59–1.87, P = 0.86). The statistical heterogeneity was low (I2 = 0%, P = 0.8). Both trials were judged to be at 
high risk of bias in two or more domains. None of the trials selected for analysis reported follow up longer than 
five years. Both trials started recruitment after 2000. The GRADE level of evidence for this outcome was judged 
to be moderate.
Figure 2. (a) Risk of bias graph: review authors’ judgements about each risk of bias item presented as 
percentages across all included studies. (b) Risk of bias summary: review authors’ judgements about each risk of 
bias item for each included study.
www.nature.com/scientificreports/
7SCIENTIfIC RepoRTS |  (2018) 8:4458  | DOI:10.1038/s41598-018-22356-z
Mortality during follow up. Data on long-term mortality were reported in two studies13,14. In the CEA group 
(432 patients), long-term mortality was 9.5%, and in the CAS group (1157 patients), it was 12.3% (OR: 0.79, 95% 
CI: 0.55–1.15, P = 0.22). There was no significant between-study heterogeneity (I2 = 0%, P = 0.74). Both trials 
were judged to be at high risk of bias in two or more domains. None of the trials selected for analysis reported 
follow up longer than five years. Both trials started recruitment after 2000. The GRADE level of evidence for this 
outcome was judged to be moderate.
Figure 3. Forest plots of comparisons of CEA vs. BMT). The solid squares denote the odds ratios (ORs) or risk 
difference (RD). The horizontal lines represent the 95% confidence intervals (CIs), and the diamond denotes the 
pooled effect size. BMT, best medical therapy; CEA, carotid endarterectomy; M-H, Mantel Haenszel test; MI, 
myocardial infarction; TIA, transient ischaemic attack.
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Ipsilateral minor stroke/TIA during follow up. Data on long-term ipsilateral minor stroke/TIA were reported 
in one trial14. In the CEA group (68 patients), no minor ipsilateral stroke/TIA occurred during follow up, and in 
the CAS group (68 patients), one patient developed a TIA during the follow-up period (1.5%) (OR: 0.33, 95% CI: 
0.01–8.21, P = 0.5). The GRADE level of evidence for this outcome was judged to be low.
MI during follow up. No data on MI during follow up were reported in the selected trials.
Figure 4. Forest plots of comparisons of CEA vs. CAS. The solid squares denote the odds ratios (ORs) or risk 
difference (RD). The horizontal lines represent the 95% confidence intervals (CIs), and the diamond denotes 
the pooled effect size. CAS, carotid stenting; CEA, carotid endarterectomy; M-H, Mantel Haenszel test; MI, 
myocardial infarction; TIA, transient ischaemic attack.
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CAS vs. BMT. There was no RCT comparing clinical outcomes between CAS and BMT.
Network meta-analysis. The geometry of the network of interventions for the primary outcomes yielded an open 
network without closed loops, as only the SPACE-212 trial included all three treatment groups, reporting 30-day 
outcome data only. This has led to limited diversity. Excluding the SPACE-2 trial12, each comparison is repre-
sented only by indirect comparisons (CEA vs BMT or CEA vs CAS); no trial provided direct evidence between 
CAS and BMT.
All but two studies15,18 reported 30-day mortality data. Considering BMT as the reference treatment, ORs and 
95% CIs for 30-day mortality were as follows: CAS, 8.41 (2.16–32.71) and CEA, 5.42 (1.85–15.95) with the result 
favouring BMT (Table 3). For this outcome parameter, the probability of BMT to be the best treatment was 99.9%.
Five trials provided data on long-term mortality9,10,13–15. With CEA as the reference, ORs and 95% CIs for 
long-term mortality were as follows: BMT, 1.43 (0.89–2.30) and CAS, 1.20 (0.65–2.21), with the result favouring 
CEA without reaching statistical significance (Table 3). For long-term mortality, the probabilities of CEA, CAS 
and BMT to be the best treatment were 66.6%, 27.6% and 5.8% respectively.
All but one trial15 reported data on 30-day ipsilateral stroke. With BMT as reference treatment, ORs and 95% 
CIs for 30-day ipsilateral stroke were as follows: CAS, 2.37(1.07–5.26) and CEA, 1.52(0.48–4.77), with the result 
favouring BMT (Table 3). For this outcome, the probability of BMT to be the best treatment was 100%.
Six trials provided data on long-term ipsilateral stroke9,10,13,15,18,19. With CEA as the reference, ORs and 95% 
CIs for long-term ipsilateral stroke were as follows: BMT, 1.69 (1.41–2.02) and CAS, 0.97 (0.55–1.72), with sta-
tistically significant results in favour of CEA over BMT only (Table 3). For ipsilateral stroke during follow up, the 
probabilities of CEA, CAS and BMT to be the best treatment were 46.4%, 53.6% and 0%, respectively.
The results from network meta-analysis predictive interval showed that future trails are highly likely to change 
the direction of the treatment effect for patients with asymptomatic carotid disease, particularly so for BMT.
Discussion
We conducted a pairwise and network meta-analysis of treatment strategies for asymptomatic carotid disease 
including a total of 8954 patients from 11 randomised clinical trials. Pairwise treatment meta-analysis showed 
that CEA is superior to BMT in reducing the risk of long-term mortality and stroke. There were no statistical sig-
nificant differences between CEA and CAS in terms of peri-interventional or long term ipsilateral stoke/mortality.
The value of CEA in reducing the risk of stroke in asymptomatic carotid artery stenosis is predominantly 
based on two seminal studies performed in the 1990s. The ACAS9 was a well-conducted RCT that was halted 
at 2.7 years because of a projected 5.9% absolute risk reduction at five years favouring CEA. BMT in this trail 
were only in the form of Aspirin and a general discussion in cardiovascular risk reduction factors. The ACST 
trial10 randomized 3120 asymptomatic carotid artery stenosis patients to immediate CEA or delayed surgery for 
symptoms only. Combining perioperative events and strokes, net risks were 6.9% vs. 10.9% at 5 years and 13.4% 
vs. 17.9% at 10 years.BMT improved significantly during these ten years with 82% of patient on lipid lowering by 
drugs by the end of trail compare to only 7% at the beginning of the trail.
In 2016, the results from two large RCTs comparing CEA with CAS in asymptomatic carotid stenosis patient 
were published. The CREST trial21 and ACT 113 resolved the durability dilemma with CAS. However, these trials 
did not resolve the issue of generalisability of these findings into routine clinical practice, where rates of death and 
stroke may be much higher among patients undergoing carotid stenting22.
In CEA vs. BMT, the quality of the evidence was judged to be high according to the GRADE system. This was 
reduced to moderate/low for CEA vs. CAS as all trials included in the analysis were judged to be at high risk of 
bias in two or more domains.
Systematic review23 of 47 studies (6 RCTs and 41 observational studies) investigating the evidence on man-
agement strategies for asymptomatic carotid stenosis also concluded that the evidence was not sufficiently robust 
or applicable to current clinical practice to allow clinicians to draw confident conclusions on the comparative 
effectiveness of management strategies for adults with asymptomatic carotid stenosis. Moresoli et al.24, published 
a meta-analysis of 11 studies (5 RCTs and 6 observational studies) on CAS vs CEA in asymptomatic carotid dis-
ease. The results of this meta-analysis corroborate our findings as there was no clinically significant differences 
between treatments for long-term stroke (RR, 1.24; 95% CI, 0.76–2.03) and the composite outcome of periproce-
dural stroke, death or MI, or long-term ipsilateral stroke (RR, 0.92; 95% CI, 0.70–1.21). Most recently, Kakkos SK 
et al.25 published a meta-analysis of 9 RCTs comparing CEA with CAS in asymptomatic carotid disease patients. 
Regarding the long-term outcome of stroke or death rate at 30 days plus ipsilateral stroke during follow-up, this 
was significantly higher for CAS (3.64%) than for CEA (2.45%) (OR, 1.51; 95% CI, 1.02–2.24; P = 0.04; I2 = 0%). 
However, quality of evidence for all stroke outcomes was graded moderate.
The network meta-analysis is the first to be undertaken in this area. It demonstrates that CAS and CEA 
increase the risk of death and ipsilateral stroke at 30 days compared to BMT. This is an unsurprising finding given 
the well reported risks of revascularisation interventions. The network meta-analysis results favour CEA in the 
long term, but this finding is less conclusive.
CREST-226 and ACST-227 trials are currently running to provide level 1 evidence in regards of treatment 
strategy for asymptomatic carotid artery disease. CREST-2 consists of 2 parallel, RCTs. One trial will compare 
BMT to CEA BMT. The parallel trial will compare BMT to CAS plus BMT. An estimated 2480 participants will 
be enrolled in CREST-2 at approximately 120 sites in the United States and in several Canadian sites. ACST-2 is 
a large international RCT comparing CEA versus CAS in patients with asymptomatic carotid stenosis. ACST-2 is 
currently recruiting patients from over 112 centres in over 20 countries worldwide. The trial is on track to recruit 
3600 patients by 2019.
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The results of our review should be interpreted with caution in view of the following limitations. The two 
major limitations to the pair-wise meta-analysis are variation in follow up period together with significant het-
erogeneity in BMT within and between the studies. Follow up period were between 30-days and 9 years. This 
variation will have an effect in reporting outcome measures using OR. This is particularly true when event rate 
is low, as in carotid trials. In terms of BMT, only one trail15 adhered to current guidelines of aggressive medical 
therapy (blood pressure control, DM treatment, lipid lowering agents) together with lifestyle modification (exer-
cise, smoking cessation and weight reduction). Antiplatelet were the only components of BMT in earlier trails 
with introduction to statin treatment in late 90s. No sufficient data are provided by the randomised clinical trials 
included in our review to allow us to perform meta-regression analysis to investigate the effect of statin and/
or aspirin on the outcomes. In addition, within CEA/CAS trial patients received different BMT regime (dual 
antiplatelet treatment if were allocated to CAS). However we tried to overcome these limitations by conducting 
sensitivity analysis excluding old studies and those with <5 years follow up.
There were also limitations in the NMA. The network geometry did not provide any closed loops across the 
competing interventions except for one trial that provided data on 30-day ipsilateral stroke only; therefore, we 
were not able to assess inconsistency between direct and indirect evidence. There was no direct comparison 
between CAS and BMT. There was a different time span between trials comparing CEA vs. BMT (1997–2015) 
and CEA vs. CAS (2004–2016), which might challenge transitivity (assumption of similarity in the study char-
acteristics between trails). Transitivity might be also challenged by the variation in the components of BMT and 
variation in the inclusion criteria. Similarly, the difference in follow up across trials and across the network may 
introduce heterogeneity and inconsistency, respectively.
Conclusions
Surgical intervention with CEA is superior to BMT in preventing long term ipsilateral stroke/mortality in asymp-
tomatic carotid disease, but there is probably no difference between CEA and CAS. CREST-2 will clarify whether 




BMT 99.9 (99.8%) 0.12 (0.03, 0.46) 0.18 (0.06, 0.54)
CAS 8.41 (2.16, 32.71) 7.7 (0.2%) 1.55 (0.68, 3.54)
CEA 5.42 (1.85, 15.95) 0.65 (0.28, 1.47) 42.4 (0.0%)
Long-term mortality
BMT 20.1(5.8%) 1.19 (0.54, 2.61) 1.43 (0.89, 2.30)
CAS 0.84 (0.38, 1.84) 47.6 (27.6%) 1.20 (0.65, 2.21)
CEA 0.70 (0.43, 1.12) 0.83 (0.45, 1.53) 82.3 (66.6%)
30-day ipsilateral stroke
BMT 100 (100%) 0.15 (0.06, 0.39) 0.24 (0.12, 0.48)
CAS 6.83 (2.60, 17.97) 4.3 (0%) 1.65 (0.81, 3.34)
CEA 4.15 (2.09, 8.22) 0.61 (0.30, 1.23) 45.7 (0%)
Long-term ipsilateral stroke
BMT 1.8 (0%) 1.73 (0.95, 3.15) 1.69 (1.41, 2.02)
CAS 0.58 (0.32, 1.05) 75.0 (53.6%) 0.97 (0.55, 1.72)
CEA 0.59 (0.50, 0.71) 1.03 (0.58, 1.82) 73.2 (46.4%)
30-day myocardial infarction
BMT 79.9 (60.7%) 0.69 (0.05, 9.94) 0.09 (0.01, 0.65)
CAS 1.45 (0.10, 20.77) 69.0 (39.3%) 0.13 (0.02, 0.79)
CEA 11.04 (1.53, 79.53) 7.64 (1.27, 46.04) 1.2 (0.0%)
30-day ipsilateral minor stroke/TIA
BMT 87.5 (76.4%) 0.42 (0.19, 0.93) 0.66 (0.21, 2.08)
CAS 2.37 (1.07, 5.26) 9.5 (22.3%) 1.56 (0.62, 3.97)
CEA 1.52 (0.48, 4.77) 0.64 (0.25, 1.62) 52.9 (1.3%)
Long-term ipsilateral minor stroke/TIA
BMT 24.3 (0.2%) 1.08 (0.04, 29.89) 3.29 (1.45, 7.46)
CAS 0.93 (0.03, 25.64) 38.5 (48.1%) 3.04 (0.01, 8.21)
CEA 0.30 (0.13, 0.69) 0.33 (0.01, 8.21) 87.2 (51.7%)
Table 3. Network meta-analyses league table. Estimates are presented as odds ratio (OR) with 95% confidence 
interval (CI) in parentheses. ORs above 1 suggest that the treatment listed in the upper row is superior; ORs 
below 1 suggest that the treatment listed in the left column is superior. Surface under the cumulative ranking 
curve values (SUCRAs) are given in the diagonal and the probability of being the best treatment in parentheses. 
Statistically significant values are given in bold. BMT, best medical therapy; CAS, carotid stenting; CEA, carotid 
endarterectomy; TIA, transient ischaemic attack.
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Methods
Design. This systematic review followed the guidelines of the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) Extension Statement for Reporting of Systematic Reviews Incorporating 
Network Meta-analyses of Health Care Interventions28. The International Prospective Register of Systematic 
Reviews (PROSPERO) registration number of this protocol is CRD 42016046153.
Criteria for considering studies for this review. Types of studies. Only randomised controlled trials 
(RCTs) investigating the outcomes of CEA, CAS and BMT in asymptomatic carotid disease were considered in 
this review.
Types of participants. We included any patients (no age or gender restriction) diagnosed with carotid stenosis 
>50% without any neurological symptoms indicating a cerebrovascular event during the 180 days preceding initi-
ation of treatment for carotid disease. The diagnosis of carotid disease should have been established with objective 
diagnostic measures, e.g. duplex ultrasonography, magnetic resonance (MR) angiography, digital subtraction 
angiography (DSA), or computed tomographic (CT) angiography.
Types of interventions. We planned to compare outcomes of patients with asymptomatic carotid disease under-
going treatment with CEA, CAS and BMT. CEA could have been performed under general or local anaesthesia. 
Any technique of CEA was considered including conventional endarterectomy with direct or patch closure or 
the eversion technique. CAS could have been performed with or without a cerebral protective device (CPD). 
We considered any type of stent including a closed or open cell design. BMT was implemented according to 
evidence-based guidelines; it mainly consisted of optimal antiplatelet therapy according to clinical practice at 
the participating centres, cholesterol-lowering agents (e.g. statin), antihypertensive medication and targeted risk 
factor modification.
Types of outcome measures. Primary outcomes
•	 Death and stroke occurring within 30 days of treatment or during the hospital stay for the index procedure 
(CEA or CAS) and during follow up.
Secondary outcomes
•	 Myocardial infarction (MI) occurring in the perioperative period (within 30 days or during the hospital stay) 
and during follow up.
•	 Transient ischemic attack (TIA) occurring in the perioperative period (within 30 days or during the hospital 
stay) and during follow up.
Search methods for identification of studies. The literature search strategy was developed in consulta-
tion with a clinical information specialist. Eligible studies were identified by searching Cochrane Central Register 
of Controlled Trials (CENTRAL), Excerpta Medica database (EMBASE), U.S. National Library of Medicine’s 
database (MEDLINE), Cumulative Index to Nursing and Allied Health Literature (CINAHL). World Health 
Organization (WHO) International Clinical Trials Registry and the ISRCTN Register was searched for on-going 
clinical trials. The final search was carried out in October 2016. The search was not restricted to any language. The 
literature search strategy is presented in Appendix I.
Data extraction and management. Two review authors (MB, IR) independently evaluated the studies 
and selected the studied that fulfilled the inclusion criteria for this review. A third author (GAA) then assess all 
the selected studie and ensure their eligibility for the inclusion criteria and also acted as an adjudicator in the 
event of disagreement.
We developed a data extraction sheet, which was pilot-tested and refined accordingly. One review author 
(MB) extracted the data from the selected studies and a second review author (IR) crosschecked the collected 
data. Disagreements were resolved by discussion between the authors. The following data were collected:
•	 Study-related information (first author, year of publication, single-centre or multi-centre study).
•	 Baseline demographics and clinical characteristics of the study populations (age, gender, diabetes mellitus, 
hypertension, type of carotid intervention, type of antiplatelet therapy).
•	 Outcome data, as outlined above.
Assessment of risk of bias in included studies. We applied the Cochrane tool for the assessment of the 
risk of bias of the selected trials29. Briefly, this tool evaluates six main domains: random sequence generation and 
allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of 
outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting 
bias), and other sources of bias. For each individual domain, we classified studies into low, unclear, or high risk 
of bias.
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The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) working group system 
was utilised for grading the quality of evidence as high, moderate, low and very low, based on directness of evi-
dence, within-study risk of bias, precision of effects estimates, heterogeneity, and risk of publication bias30.
Methods of analysis. We used the RevMan 5.3 software (Cochrane collaboration, Copenhagen, Denmark) 
for pair-wise meta-analyses. Treatment effect estimates were calculated using the odds ratio (OR) or risk dif-
ference (RD) and 95% confidence interval (CI) to reflect the uncertainty of point estimate of effects. We based 
calculations using an intention-to-treat approach and all randomized participants were included in the analysis 
regardless of loss to follow up. The unit of analysis was the individual patient. For data synthesis, we used a 
fixed-effect model to calculate the pooled treatment effect and 95% CI for dichotomous outcome variables. We 
used a random-effects model when we found significant heterogeneity (defined as I2 greater than 75%). We cre-
ated a forest plot for each treatment effect.
We assessed inter-study heterogeneity visually using a forest plot. We also calculated the I2 statistic to measure 
the amount of interstudy heterogeneity. We considered I2 values less than 50% as indicative of low heterogeneity, 
I2 values between 50% and 75% as indicative of moderate heterogeneity, and I2 values greater than 75% as indic-
ative of significant heterogeneity.
We planned to construct a funnel plot to test for reporting bias in meta-analyses that included 10 or more 
studies. We planned to assess publication bias visually evaluating the symmetry of the funnel plots. We also 
planned to mathematically estimate publication bias using the Egger’s regression intercept.
We performed sensitivity analysis by sequentially excluding trials with a high risk of bias in two or more 
domains and performed a pooled sensitivity analysis in order to assess whether the included studies, deemed to 
be biased, impacted the final analysis. We also performed separate analysis of follow-up outcome data for studies 
providing follow up longer than five years. We performed sensitivity analysis excluding old studies (where the 
recruitment period started before 2000).
We performed a network meta-analysis in Stata version 13 (College Station, Texas, USA) using the network 
command and self-programmed Stata routines31–33. We used the restricted maximum likelihood method to esti-
mate heterogeneity assuming a common estimate for the heterogeneity variance across the different comparisons. 
We estimated the ranking probabilities for all treatments of being at each possible rank for each intervention. We 
obtained a hierarchy of the competing interventions using rankograms and the surface under the cumulative 
ranking curve (SUCRA) and mean ranks34. We produced the relevant plots using the suite of Stata commands by 
Chaimani et al.33.
Data availability. The data spread sheet generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
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